Catalyst Pharmaceuticals (NASDAQ:CPRX) reported fourth-quarter and full-year 2025 results that management said reflected ...

Q4 2025 Management View Richard John Daly, President and CEO, stated that "2025 was defined by notable growth as evidenced by another year of record revenues, execution of our strategy to maximize the ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best cheap biotech stocks to buy now. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported record fiscal Q4 and record full year 2025 ...

Moby Strategic Performance and Operational Drivers. Achieved record 2025 revenues of $589 million, driven by 20.3% g ...

Catalyst Pharmaceuticals, Inc. is upgraded to Hold as FIRDAPSE's loss-of-exclusivity risk is deferred to 2035, stabilizing its revenue base. CPRX's AGAMREE launch outpaces expectations, with 115% Y/Y ...

Catalyst Pharmaceuticals, Inc. ('Catalyst' or 'Company') (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...